502 related articles for article (PubMed ID: 35875026)
1. Triple-Negative Breast Cancer Analysis Based on Metabolic Gene Classification and Immunotherapy.
Zhou Y; Che Y; Fu Z; Zhang H; Wu H
Front Public Health; 2022; 10():902378. PubMed ID: 35875026
[TBL] [Abstract][Full Text] [Related]
2. Construction of Metabolic Molecular Classification and Immune Characteristics for the Prognosis Prediction of Ovarian Cancer.
Wang K; He H; Feng X
J Immunol Res; 2022; 2022():2359349. PubMed ID: 35800989
[TBL] [Abstract][Full Text] [Related]
3. Development of Prognostic Features of Hepatocellular Carcinoma Based on Metabolic Gene Classification and Immune and Oxidative Stress Characteristic Analysis.
Cui S; Zhang M; Bai S; Bi Y; Cong S; Jin S; Li S; He H; Zhang J
Oxid Med Cell Longev; 2023; 2023():1847700. PubMed ID: 36860731
[TBL] [Abstract][Full Text] [Related]
4. A novel fatty-acid metabolism-based classification for triple negative breast cancer.
Yang X; Tang W; He Y; An H; Wang J
Aging (Albany NY); 2023 Feb; 15(4):1177-1198. PubMed ID: 36880837
[TBL] [Abstract][Full Text] [Related]
5. Regulatory T cells are associated with the tumor immune microenvironment and immunotherapy response in triple-negative breast cancer.
Huang P; Zhou X; Zheng M; Yu Y; Jin G; Zhang S
Front Immunol; 2023; 14():1263537. PubMed ID: 37767092
[TBL] [Abstract][Full Text] [Related]
6. Research and experimental verification on the mechanisms of cellular senescence in triple-negative breast cancer.
Cao T; Huang M; Huang X; Tang T
PeerJ; 2024; 12():e16935. PubMed ID: 38435998
[TBL] [Abstract][Full Text] [Related]
7. A novel model associated with tumor microenvironment on predicting prognosis and immunotherapy in triple negative breast cancer.
Zhang J; Zhang M; Tian Q; Yang J
Clin Exp Med; 2023 Nov; 23(7):3867-3881. PubMed ID: 37219794
[TBL] [Abstract][Full Text] [Related]
8. A Machine Learning Model to Predict the Triple Negative Breast Cancer Immune Subtype.
Chen Z; Wang M; De Wilde RL; Feng R; Su M; Torres-de la Roche LA; Shi W
Front Immunol; 2021; 12():749459. PubMed ID: 34603338
[TBL] [Abstract][Full Text] [Related]
9. Development of an ubiquitin-proteasome system signature for predicting prognosis and providing therapeutic guidance for patients with triple-negative breast cancer.
Chen X; Ren C; Zhou Z; Chen J; Fan X; Li X; Chen J; Zhu J
J Gene Med; 2024 Jan; 26(1):e3584. PubMed ID: 37605934
[TBL] [Abstract][Full Text] [Related]
10. Highly heterogeneous-related genes of triple-negative breast cancer: potential diagnostic and prognostic biomarkers.
Liu Y; Teng L; Fu S; Wang G; Li Z; Ding C; Wang H; Bi L
BMC Cancer; 2021 May; 21(1):644. PubMed ID: 34053447
[TBL] [Abstract][Full Text] [Related]
11. Establishment and validation of an individualized macrophage-related gene signature to predict overall survival in patients with triple negative breast cancer.
Su P; Peng Z; Xu B; Yang B; Jin F
PeerJ; 2021; 9():e12383. PubMed ID: 34900411
[TBL] [Abstract][Full Text] [Related]
12. Combination of Immune-Related Network and Molecular Typing Analysis Defines a Three-Gene Signature for Predicting Prognosis of Triple-Negative Breast Cancer.
Zhang J; Pan S; Han C; Jin H; Sun Q; Du J; Han X
Biomolecules; 2022 Oct; 12(11):. PubMed ID: 36358906
[TBL] [Abstract][Full Text] [Related]
13. Novel molecular insights into pyroptosis in triple-negative breast cancer prognosis and immunotherapy.
Yu B; Luo J; Yang Y; Zhen K; Shen B
J Gene Med; 2024 Jan; 26(1):e3645. PubMed ID: 38041540
[TBL] [Abstract][Full Text] [Related]
14. Identification and Validation of a Novel Glycolysis-Related Gene Signature for Predicting the Prognosis and Therapeutic Response in Triple-Negative Breast Cancer.
Zheng J; Zhang YF; Han GH; Fan MY; Du MH; Zhang GC; Zhang B; Qiao J; Zhang SX; Cao JM
Adv Ther; 2023 Jan; 40(1):310-330. PubMed ID: 36316558
[TBL] [Abstract][Full Text] [Related]
15. Development and verification of a novel immunogenic cell death-related signature for predicting the prognosis and immune infiltration in triple-negative breast cancer.
Li J; Li Z; Yang W; Pan J; You H; Yang L; Zhang X
Cancer Rep (Hoboken); 2024 Mar; 7(3):e2007. PubMed ID: 38425247
[TBL] [Abstract][Full Text] [Related]
16. Natural killer cell-related prognostic risk model predicts prognosis and treatment outcomes in triple-negative breast cancer.
Liu Z; Ding M; Qiu P; Pan K; Guo Q
Front Immunol; 2023; 14():1200282. PubMed ID: 37520534
[TBL] [Abstract][Full Text] [Related]
17. Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women.
O'Meara T; Safonov A; Casadevall D; Qing T; Silber A; Killelea B; Hatzis C; Pusztai L
Breast Cancer Res Treat; 2019 May; 175(1):247-259. PubMed ID: 30725384
[TBL] [Abstract][Full Text] [Related]
18. Prognosis in different subtypes of metaplastic breast cancer: a population-based analysis.
He X; Ji J; Dong R; Liu H; Dai X; Wang C; Esteva FJ; Yeung SJ
Breast Cancer Res Treat; 2019 Jan; 173(2):329-341. PubMed ID: 30341462
[TBL] [Abstract][Full Text] [Related]
19. Construction of a prognostic model for triple-negative breast cancer based on immune-related genes, and associations between the tumor immune microenvironment and immunological therapy.
Zhu Y; Tao LF; Liu JY; Wang YX; Huang H; Jiang YN; Qian WF
Cancer Med; 2023 Jul; 12(14):15704-15719. PubMed ID: 37306188
[TBL] [Abstract][Full Text] [Related]
20. Immunity and Extracellular Matrix Characteristics of Breast Cancer Subtypes Based on Identification by T Helper Cells Profiling.
Zhou Y; Tian Q; Gao H; Zhu L; Zhang Y; Zhang C; Yang J; Wang B
Front Immunol; 2022; 13():859581. PubMed ID: 35795662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]